Senti Biosciences (SNTI) news
Recent news
Senti Biosciences - 25,555,024 shares of common stock offered by selling securityholders - SEC filing
Senti Biosciences, Inc. has filed with the U.S. Securities and Exchange Commission (SEC) to offer 25,555,024 shares of its common stock by selling securityholders. The offering is part of a registered secondary transaction, in which existing shareholders will sell their shares to the public. The…
AInvest Wire · Sep 24, 2026ImportantSenti Biosciences stock soars 220% on positive trial data
Senti Biosciences stock soars 220% on positive trial data Senti Biosciences, Inc. (SNTI), a preclinical biotechnology company specializing in next-generation cell and gene therapies, experienced a significant surge in its stock price on December 2, 2024. The company's shares soared by an impressive…
AInvest Wire · Dec 2, 2024ImportantSenti Biosciences shares surge 142% in premarket trading on new strategic collaboration with Celest Therapeutics for clinical development of senti-301a in China
AInvest Wire · Nov 7, 2023ImportantSenti Biosciences surges 40% premarket after receiving a notice of allowance for its U.S. patent application 17/338,528
AInvest Wire · Oct 4, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.